Robert Dreicer, MD, MS, MACP, FASCO, Michael S. Cookson, MD, MMHC, Oliver Sartor, MD, and Neal D. Shore, MD, FACS, prepared useful practice aids pertaining to prostate cancer management for this CME activity titled "Science and Stories: Navigating the Prostate Cancer Landscape - Urologists at the Intersection of Emerging Evidence and Patient Centric Care." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2JFhjpM. CME credit will be available until June 26, 2019.

1. ADT: androgen deprivation therapy; PSA: prostate-specific antigen.
a
For symptomatic patients with bone metastases only.
1. Adapted from: Chang JA et al. Nat Rev Clin Oncol. 2014;11:308-323.
Prostate Cancer: Clinical States and
Treatment Options1
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
Access the activity,“Science and Stories: Navigating the Prostate Cancer Landscape,”at www.peerview.com/NVW40.
Neoadjuvant
Clinically
localized
disease
Clinical
metastases
Castrate
Pre-chemotherapy
Sipuleucel-T
Abiraterone
Enzalutamide
Radium-223a
Clinical
metastases
Castrate
Post-chemotherapy
Enzalutamide
Cabazitaxel
Abiraterone
Radium-223a
Clinical
metastases
Castrate
First-line
chemotherapy
Docetaxel
Abiraterone +
prednisone
Clinical
metastases
Non-castrate
Rising PSA
ADT
Rising PSA
Castrate
Apalutamide
Adjuvant Salvage

2. Key Ongoing Phase 3 Clinical Trials
in Prostate Cancer1
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
Localized or Locally Advanced Prostate Cancer
ATLAS
(NCT02531516)
GnRH agonist +
apalutamide vs GnRH
agonist + bicalutamide
High-risk patients
receiving primary RT
ECOG PS 0 or 1
Metastasis-free survival OS
Active
Not recruiting
Planned
N = 350
Recruiting
Planned
N = 1500
Non-Metastatic CRPC
Metastasis-free survival
Active
Has results
N = 1207
Metastasis-free survival
Active
Has results
N = 1401
Metastasis-free survival
EMBARK
(NCT02319837)
Enzalutamide +
leuprolide vs enzalutamide
vs placebo + leuprolide
High-risk
hormone-sensitive
patients progressing
after definitive therapy
(radical prostatectomy or
radiotherapy or both)
Metastasis-free survival
Recruiting
Planned
N = 1860
Treatment
and population
Treatment
and population
Primary endpoint
Primary endpoint
Active
Not recruiting
Planned
N = 1502
SPARTAN
(NCT01946204)
Apalutamide vs
placebo
High-risk
castration-resistant
patients
ECOG PS 0 or 1
PROSPER
(NCT02003924)
Enzalutamide vs
placebo
Ongoing ADT
or prior bilateral
orchiectomy
ECOG PS 0 or 1
ARAMIS
(NCT02200614)
Darolutamide vs
placebo
High-risk
castration-resistant
patients
ECOG PS 0 or 1
LoLA PC
(NCT00116142)
Androgen suppression +
RT with or without
docetaxel
High-risk patients
ECOG PS 0 or 1
Access the activity,“Science and Stories: Navigating the Prostate Cancer Landscape,”at www.peerview.com/NVW40.

3. Key Ongoing Phase 3 Clinical Trials
in Prostate Cancer1
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
Metastatic Hormone-Sensitive Prostate Cancer
TITAN
(NCT02489318)
ADT + placebo vs
ADT + apalutamide
Newly-diagnosed
or previously treated
ECOG PS 0 or 1
OS and radiographic PFS
Active
Not recruiting
Planned
N = 1052
ARASENS
(NCT02799602)
ADT + docetaxel +
placebo vs ADT +
darolutamide +
docetaxel
Newly-diagnosed
metastatic disease
ECOG PS 0 or 1
OS
Recruiting
Planned
N = 1300
OS and PFS
Recruiting
Planned
N = 1168
LATITUDE
(NCT01715285)
Abiraterone +
low-dose prednisone
+ ADT vs ADT alone
High-risk patients
ECOG PS 0-2
OS and radiographic PFS
Active
Has results
N = 1199
Radiographic PFS
Active
Not recruiting
Planned
N = 1150
Treatment
and population
Treatment
and population
Primary endpoint
Primary endpoint
ARCHES
(NCT02677896)
ADT + enzalutamide
vs ADT + placebo
Ongoing ADT or prior
bilateral orchiectomy
ECOG PS 0 or 1
PEACE1
(NCT01957436)
ADT + docetaxel +/-
local RT +/-
abiraterone
ECOG PS 0 or 1
Access the activity,“Science and Stories: Navigating the Prostate Cancer Landscape,”at www.peerview.com/NVW40.

4. ADT: androgen deprivation therapy; AR: androgen receptor; CRPC: castrate-resistant prostate cancer; ECOG: Eastern Cooperative Oncology Group; GnRH: gonadotropin-releasing hormone agonist; OS: overall survival; PFS: progression-free survival; PS: performance status;
RT: radiotherapy; vs: versus.
1. http://www.clinicaltrials.gov. Accessed April 23, 2018.
Key Ongoing Phase 3 Clinical Trials
in Prostate Cancer1
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
Access the activity,“Science and Stories: Navigating the Prostate Cancer Landscape,”at www.peerview.com/NVW40.
Metastatic CRPC
Radiographic PFS
NCT02257736
Apalutamide +
abiraterone +
prednisone vs
abiraterone +
prednisone
Chemotherapy-naïve
patients
Radiographic PFS
Recruiting
Planned
N = 400
ALLIANCE A031201
(NCT01949337)
Enzalutamide +
abiraterone +
prednisone vs
enzalutamide alone
Ongoing ADT or prior
bilateral orchiectomy
ECOG PS 0 or 1
OS
Active
Not recruiting
Planned
N = 1311
Active
Not recruiting
Planned
N = 983
IPATential150
(NCT03072238)
Ipatasertib + abiraterone +
prednisone/prednisolone vs
placebo + abiraterone +
prednisone/prednisolone
Previously untreated,
asymptomatic or mildly
symptomaticdisease;ongoing
ADTorpriorbilateralorchiectomy
ECOG PS 0 or 1
Radiographic PFS
PROfound Study
(NCT02987543)
Olaparib vs enzalutamide
or abiraterone
Previously treated with
abiraterone and/or
enzalutamide;
ongoing ADT or prior
bilateral orchiectomy
Radiographic PFS
ERA 223
(NCT02043678)
Radium-223 dichloride +
abiraterone + prednisone/
prednisolone vs placebo +
abiraterone + prednisone/
prednisolone
Asymptomatic or mildly
symptomatic; chemotherapy-naïve
bone-predominant disease
ECOG PS 0 or 1
Symptomatic skeletal event-free survival
Active
Not recruiting
Planned
N = 806
Treatment
and population
Treatment
and population
Primary endpoint
Primary endpoint
Recruiting
Planned
N = 850
Recruiting
Planned
N = 340
TRITON3
(NCT02975934)
Rucaparib vs physician's
choice of therapy
Patients with
deleterious mutation in
a BRCA1/2 or ATM gene;
1 prior next generation
AR-targeted therapy